PacBio Announces Appointment of David Ruggiero as Head of Global Sales & Service
PacBio (NASDAQ: PACB) has appointed David Ruggiero as the new Global Head of Sales & Service, effective February 10, 2025. Ruggiero brings over 20 years of sales leadership experience in technology and life sciences sectors. His previous roles include Senior Vice President, North America at Sinch AB, and senior positions at Zoom Video Communications, Microsoft , and Thermo Fisher Scientific, where he served as Chief Commercial Officer for the Life Sciences Solutions Group.
In his new role, Ruggiero will lead PacBio's global sales and service operations, focusing on accelerating the adoption of the company's sequencing platforms and enhancing worldwide customer support. The appointment aligns with PacBio's strategy to expand its global presence and deliver innovative sequencing solutions to customers.
PacBio (NASDAQ: PACB) ha nominato David Ruggiero nuovo Responsabile Globale delle Vendite e dei Servizi, con effetto dal 10 febbraio 2025. Ruggiero porta con sé oltre 20 anni di esperienza nella leadership commerciale nei settori della tecnologia e delle scienze della vita. I suoi ruoli precedenti includono Vicepresidente Senior per il Nord America presso Sinch AB, e posizioni dirigenziali presso Zoom Video Communications, Microsoft e Thermo Fisher Scientific, dove ha ricoperto il ruolo di Chief Commercial Officer per il Life Sciences Solutions Group.
Nel suo nuovo ruolo, Ruggiero guiderà le operazioni globali di vendita e servizio di PacBio, concentrandosi sull'accelerazione dell'adozione delle piattaforme di sequenziamento dell'azienda e sul miglioramento del supporto clienti a livello mondiale. Questa nomina è in linea con la strategia di PacBio di espandere la propria presenza globale e fornire soluzioni di sequenziamento innovative ai clienti.
PacBio (NASDAQ: PACB) ha nombrado a David Ruggiero como nuevo Director Global de Ventas y Servicio, a partir del 10 de febrero de 2025. Ruggiero aporta más de 20 años de experiencia en liderazgo de ventas en los sectores de tecnología y ciencias de la vida. Sus roles anteriores incluyen Vicepresidente Senior de Norteamérica en Sinch AB, así como posiciones senior en Zoom Video Communications, Microsoft y Thermo Fisher Scientific, donde se desempeñó como Director Comercial del Grupo de Soluciones de Ciencias de la Vida.
En su nuevo cargo, Ruggiero liderará las operaciones globales de ventas y servicio de PacBio, centrándose en acelerar la adopción de las plataformas de secuenciación de la compañía y mejorar el soporte al cliente a nivel mundial. La designación se alinea con la estrategia de PacBio de expandir su presencia global y ofrecer soluciones de secuenciación innovadoras a los clientes.
PacBio (NASDAQ: PACB)는 David Ruggiero를 2025년 2월 10일부터 새로운 글로벌 영업 및 서비스 책임자로 임명했습니다. Ruggiero는 기술 및 생명 과학 분야에서 20년 이상의 영업 리더십 경험을 가지고 있습니다. 그의 이전 직책에는 Sinch AB의 북미 시니어 부사장과 Zoom Video Communications, Microsoft 및 Thermo Fisher Scientific의 고위직이 포함되며, 이곳에서는 생명 과학 솔루션 그룹의 최고 상업 책임자를 역임했습니다.
그의 새로운 역할에서 Ruggiero는 PacBio의 글로벌 영업 및 서비스 운영을 이끌며, 회사의 시퀀싱 플랫폼 채택을 가속화하고 전 세계 고객 지원을 강화하는 데 집중할 것입니다. 이 임명은 PacBio의 글로벌 존재감을 확대하고 고객에게 혁신적인 시퀀싱 솔루션을 제공하려는 전략과 일치합니다.
PacBio (NASDAQ: PACB) a nommé David Ruggiero en tant que nouveau Responsable Mondial des Ventes et des Services, effectif à partir du 10 février 2025. Ruggiero apporte plus de 20 ans d'expérience en leadership commercial dans les secteurs de la technologie et des sciences de la vie. Ses précédents rôles incluent Vice-président Senior pour l'Amérique du Nord chez Sinch AB, ainsi que des postes importants chez Zoom Video Communications, Microsoft et Thermo Fisher Scientific, où il a été Directeur Commercial pour le groupe des Solutions en Sciences de la Vie.
Dans son nouveau rôle, Ruggiero dirigera les opérations mondiales de vente et de service de PacBio, en se concentrant sur l'accélération de l'adoption des plateformes de séquençage de l'entreprise et sur l'amélioration du support client à l'échelle mondiale. Cette nomination s'inscrit dans la stratégie de PacBio d'élargir sa présence mondiale et d'offrir des solutions de séquençage innovantes à ses clients.
PacBio (NASDAQ: PACB) hat David Ruggiero zum neuen Global Head of Sales & Service ernannt, mit Wirkung zum 10. Februar 2025. Ruggiero bringt über 20 Jahre Erfahrung in der Verkaufsleitung in den Bereichen Technologie und Lebenswissenschaften mit. Zu seinen früheren Positionen gehören Senior Vice President für Nordamerika bei Sinch AB sowie leitende Positionen bei Zoom Video Communications, Microsoft und Thermo Fisher Scientific, wo er als Chief Commercial Officer für die Life Sciences Solutions Group tätig war.
In seiner neuen Rolle wird Ruggiero die globalen Vertriebs- und Serviceoperationen von PacBio leiten und sich darauf konzentrieren, die Akzeptanz der Sequenzierungsplattformen des Unternehmens zu beschleunigen und den weltweiten Kundenservice zu verbessern. Diese Ernennung steht im Einklang mit der Strategie von PacBio, die globale Präsenz auszubauen und Kunden innovative Sequenzierungslösungen anzubieten.
- Appointment of an experienced executive with over 20 years in sales leadership
- Strong background in both technology and life sciences sectors
- Previous executive experience at major companies including Microsoft, Zoom, and Thermo Fisher Scientific
- None.
MENLO PARK, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of David Ruggiero as the company’s new Global Head of Sales & Service.
Mr. Ruggiero brings over two decades of experience in sales leadership within the technology and life sciences sectors. Prior to joining PacBio, he served as Senior Vice President, North America for Sinch AB, a leading global provider of cloud-based communication solutions for business and mobile operators. In his role he led North American sales for the enterprise, mid-market segments. Before that, he held senior sales positions at Zoom Video Communications, Microsoft Corporation, and Thermo Fisher Scientific, where, as part of Life Technologies, he was Chief Commercial Officer for the Life Sciences Solutions Group.
“We are thrilled to welcome David to the PacBio team,” said Christian Henry, President and CEO of PacBio. “His extensive experience and proven track record in creating and leading high-performing sales teams in both technology and life sciences make him an ideal fit as we continue to seek to expand our global presence and deliver innovative sequencing solutions to our customers.”
In his new role, Mr. Ruggiero will oversee PacBio’s global sales and service operations, focusing on accelerating the adoption of the company’s sequencing platforms and enhancing customer support worldwide.
“I am excited to join PacBio at such a pivotal time in the company’s growth,” said Mr. Ruggiero. “I look forward to working with the team to build on PacBio’s strong foundation and drive further success in bringing cutting-edge sequencing technologies to researchers and clinicians around the world.”
Mr. Ruggiero is expected to start on February 10, 2025.
About PacBio
Pacific Biosciences of California, Inc. (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies stem from two highly differentiated core technologies focused on accuracy, quality, and completeness, which include our HiFi long-read sequencing and our SBB® short-read sequencing technologies. Our products address solutions across a broad set of research applications, including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.
PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.
Forward Looking Statements
This press release may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including statements relating to the uses, coverage, advantages, and benefits or expected uses, advantages or benefits of using, PacBio products or technologies; efforts to continue the Company’s expansion and presence globally, including in the clinical genomics market; efforts to accelerate the adoption of the company’s sequencing platforms and enhancing customer support worldwide; and other future events. You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks, and uncertainties and could cause actual outcomes and results to differ materially from currently anticipated results, including potential performance, quality and regulatory issues; inability to expand into the clinical or other markets; and third-party claims alleging infringement of patents and proprietary rights or seeking to invalidate PacBio's patents or proprietary rights. Additional factors that could materially affect actual results can be found in PacBio's most recent filings with the Securities and Exchange Commission, including PacBio's most recent reports on Forms 8-K, 10-K, and 10-Q, and include those listed under the caption "Risk Factors." These forward-looking statements are based on current expectations and speak only as of the date hereof; except as required by law, PacBio disclaims any obligation to revise or update these forward-looking statements to reflect events or circumstances in the future, even if new information becomes available.
Contacts
Investors:
Todd Friedman
ir@pacb.com
Media:
pr@pacb.com
FAQ
When will David Ruggiero start as PacBio's (PACB) new Global Head of Sales & Service?
What is David Ruggiero's previous experience before joining PacBio (PACB)?
What will be David Ruggiero's main responsibilities at PacBio (PACB)?
How does this appointment align with PacBio's (PACB) business strategy?
